Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise

Biological Psychiatry

Volumn 83, Issue 4, 2018, Pages 311-319

  van Dyck, Christopher H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid related imaging abnormalities; Amyloid ; Amyloid oligomers; Immunotherapy; Monoclonal antibodies

Indexed keywords

ADUCANUMAB; AMYLOID BETA PROTEIN; AMYOID BETA PROTEIN MONOCLONAL ANTIBODY; BAN 2401; BAPINEUZUMAB; CRENEZUMAB; EPITOPE; GANTENERUMAB; MONOCLONAL ANTIBODY; NOOTROPIC AGENT; PONEZUMAB; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; UNSPECIFIED SIDE EFFECT; AGED; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MIDDLE AGED;

EID: 85044613077     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.08.010     Document Type: Review

References (66)

1. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 (2016), 595–608.
2. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005), 1553–1562.
3. Arai, H., Suzuki, H., Yoshiyama, T., Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: Results from two phase 2 studies. Curr Alzheimer Res 12 (2015), 242–254.
4. Pasquier, F., Sadowsky, C., Holstein, A., Leterme Gle, P., Peng, Y., Jackson, N., et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer's disease. J Alzheimer Dis 51 (2016), 1131–1143.
5. van Dyck, C.H., Sadowsky, C., Le Prince Leterme, G., Booth, K., Peng, Y., et al. Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer's disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study. J Prev Alzheimers Dis 3 (2016), 75–84.
6. Farlow, M.R., Andreasen, N., Riviere, M.E., Vostiar, I., Vitaliti, A., Sovago, J., et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther, 7, 2015, 23.
7. Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11 (2012), 597–604.
8. Montoliu-Gaya, L., Villegas, S., Abeta-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Rev Mol Med, 18, 2016, e13.
9. Sarazin, M., Dorothee, G., de Souza, L.C., Aucouturier, P., Immunotherapy in Alzheimer's disease: Do we have all the pieces of the puzzle?. Biol Psychiatry 74 (2013), 329–332.
10. Reiman, E.M., Langbaum, J.B., Fleisher, A.S., Caselli, R.J., Chen, K., Ayutyanont, N., et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26:suppl 3 (2011), 321–329.
11. Lemere, C.A., Immunotherapy for Alzheimer's disease: Hoops and hurdles. Mol Neurodegener, 8, 2013, 36.
12. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000), 916–919.
13. Black, R.S., Sperling, R.A., Safirstein, B., Motter, R.N., Pallay, A., Nichols, A., et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24 (2010), 198–203.
14. Sperling, R.A., Jack, C.R. Jr., Black, S.E., Frosch, M.P., Greenberg, S.M., Hyman, B.T., et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7 (2011), 367–385.
15. Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 (2009), 2061–2070.
16. Mohs, R.C., Knopman, D., Petersen, R.C., Ferris, S.H., Ernesto, C., Grundman, M., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11:suppl 2 (1997), S13–S21.
17. Rosen, W.G., Mohs, R.C., Davis, K.L., A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984), 1356–1364.
18. Gauthier, S., Gelinas, I., Gauthier, L., Functional disability in Alzheimer's disease. Int Psychogeriatr 9:suppl 1 (1997), 163–165.
19. Rinne, J.O., Brooks, D.J., Rossor, M.N., Fox, N.C., Bullock, R., Klunk, W.E., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9 (2010), 363–372.
20. Sperling, R., Salloway, S., Brooks, D.J., Tampieri, D., Barakos, J., Fox, N.C., et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11 (2012), 241–249.
21. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
22. Liu, E., Schmidt, M.E., Margolin, R., Sperling, R., Koeppe, R., Mason, N.S., et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85 (2015), 692–700.
23. Siemers, E.R., Sundell, K.L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 (2016), 110–120.
24. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001), 8850–8855.
25. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., Holtzman, D.M., Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295 (2002), 2264–2267.
26. Siemers, E.R., Friedrich, S., Dean, R.A., Gonzales, C.R., Farlow, M.R., Paul, S.M., et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33 (2010), 67–73.
27. Farlow, M., Arnold, S.E., van Dyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8 (2012), 261–271.
28. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
29. Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11:suppl 2 (1997), S33–S39.
30. The Lancet Neurology. Solanezumab: Too late in mild Alzheimer's disease?. Lancet Neurol, 16, 2017, 97.
31. Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., et al. The A4 study: Stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
32. Bateman, R.J., Benzinger, T.L., Berry, S., Clifford, D.B., Duggan, C., Fagan, A.M., et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13 (2017), 8–19.
33. Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., et al. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28 (2012), 49–69.
34. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69 (2012), 198–207.
35. Lasser, R., Ostrowitzki, S., Scheltens, P., Boada, M., Dubois, B., Dorflinger, E., et al. Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial. Alzheimers Dement 11:suppl (2015), 331–332.
36. Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A.L., Antoniello, K., et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32 (2012), 9677–9689.
37. Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., et al. Structure of crenezumab complex with Abeta shows loss of beta-hairpin. Sci Rep, 6, 2016, 39374.
38. Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Scheltens P, et al. (in press): Double-blind, placebo-controlled, randomized Phase II study of the anti-amyloid-beta antibody crenezumab (MABT5102A) in mild-to-moderate Alzheimer's Disease (ABBY). Neurology.
39. Crespi, G.A., Hermans, S.J., Parker, M.W., Miles, L.A., Molecular basis for mid-region amyloid-beta capture by leading Alzheimer's disease immunotherapies. Sci Rep, 5, 2015, 9649.
40. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. (2014): A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Presented at Alzheimer's Association International Conference (AAIC), Copenhagen, Denmark, July 16, 2014.
41. Salloway S, Cho W, Clayton D, Honigberg L, Rabe C, Friesenhahn M, et al. (2014): Amyloid PET imaging results from a study to evaluate the impact of crenezumab on fibrillar amyloid in patients with mild-to-moderate Alzheimer's disease. Presented at Clinical Trials on Alzheimer's Disease (CTAD), Philadelphia, PA, November 20, 2014.
42. Honigberg L, Clayton D, Cho W, Rabe C, Friesenhahn M, Ward M, et al. (2014): Biomarker results from the crenezumab anti-Aβ phase 2 biomarker trial. Presented at Clinical Trials on Alzheimer's Disease (CTAD), Philadelphia, PA, November 20–22, 2014.
43. La Porte, S.L., Bollini, S.S., Lanz, T.A., Abdiche, Y.N., Rusnak, A.S., Ho, W.H., et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 421 (2012), 525–536.
44. Landen, J.W., Zhao, Q., Cohen, S., Borrie, M., Woodward, M., Billing, C.B. Jr., et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 36 (2013), 14–23.
45. Burstein, A.H., Zhao, Q., Ross, J., Styren, S., Landen, J.W., Ma, W.W., et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 36 (2013), 8–13.
46. Miyoshi, I., Fujimoto, Y., Yamada, M., Abe, S., Zhao, Q., Cronenberger, C., et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: A multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther 51 (2013), 911–923.
47. Tucker, S., Moller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjodahl, J., et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis 43 (2015), 575–588.
48. Logovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., et al. Safety and tolerability of BAN2401—a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther, 8, 2016, 14.
49. Lannfelt, L., Moller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils—a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther, 6, 2014, 16.
50. Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P.H., Williams, L., Maier, M., et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537 (2016), 50–56.
51. Penninkilampi, R., Brothers, H.M., Eslick, G.D., Safety and efficacy of anti-amyloid-beta immunotherapy in Alzheimer's disease: A systematic review and meta-analysis. J Neuroimmune Pharmacol 12 (2017), 194–203.
52. Herrup, K., The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18 (2015), 794–799.
53. Walsh, D.M., Selkoe, D.J., A beta oligomers—a decade of discovery. J Neurochem 101 (2007), 1172–1184.
54. Cheng, I.H., Scearce-Levie, K., Legleiter, J., Palop, J.J., Gerstein, H., Bien-Ly, N., et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282 (2007), 23818–23828.
55. Horikoshi, Y., Mori, T., Maeda, M., Kinoshita, N., Sato, K., Yamaguchi, H., Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice. Biochem Biophys Res Commun 325 (2004), 384–387.
56. Bussiere, T., Bard, F., Barbour, R., Grajeda, H., Guido, T., Khan, K., et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165 (2004), 987–995.
57. Lu, J.X., Qiang, W., Yau, W.M., Schwieters, C.D., Meredith, S.C., Tycko, R., Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154 (2013), 1257–1268.
58. Wilcock, D.M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24 (2004), 6144–6151.
59. Kou, J., Kim, H., Pattanayak, A., Song, M., Lim, J.E., Taguchi, H., et al. Anti-amyloid-beta single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer's disease mouse model. J Alzheimers Dis 27 (2011), 23–38.
60. Wang, Y.J., Pollard, A., Zhong, J.H., Dong, X.Y., Wu, X.B., Zhou, H.D., et al. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30 (2009), 364–376.
61. Zhang, Y., Lee, D.H., Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist 17 (2011), 163–173.
62. Liu, Y.H., Wang, Y.R., Xiang, Y., Zhou, H.D., Giunta, B., Manucat-Tan, N.B., et al. Clearance of amyloid-beta in Alzheimer's disease: Shifting the action site from center to periphery. Mol Neurobiol 51 (2015), 1–7.
63. Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
64. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., et al. Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
65. Knopman, D.S., Jack, C.R. Jr., Lundt, E.S., Weigand, S.D., Vemuri, P., Lowe, V.J., et al. Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiol Aging 46 (2016), 32–42.
66. Landau, S.M., Breault, C., Joshi, A.D., Pontecorvo, M., Mathis, C.A., Jagust, W.J., et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med 54 (2013), 70–77.